The potency of @entity6914 : serum levels of XXXX and adrenal function during therapy with 0.05% @entity6914 in @entity1 with severe @entity483 .

@entity1 @entity16973 @entity483 @entity701 @entity6914 @entity15
BACKGROUND: Percutaneous absorption of topically applied 0.05% @entity6914 ( @entity16973 ) can be assessed indirectly by measuring @entity701 levels. A direct way is to measure systemic levels of topically applied @entity16973 . METHODS: Serum concentrations of @entity16973 were measured by liquid chromatography-tandem mass spectrometry (LC/ @entity15 / @entity15 ), and were related to serum @entity701 levels in 25 @entity1 with an exacerbation of @entity483 ( @entity483 ) before and after the first day of treatment with 0.05% @entity16973 in hospital. The body surface area (BSA) affected by @entity483 was measured. RESULTS: Before the start of 0.05% @entity16973 treatment, normal @entity701 levels were measured (0.47    0.18  mol/l) and @entity16973 concentrations could not be detected. After the first day of treatment, @entity701 levels decreased to 0.04    0.05  mol/l. Serum concentrations of @entity16973 could be detected in all @entity1 (0.112-4.504 ng/ml). Levels did not differ between @entity1 who had received two applications versus one application of 0.05% @entity16973 . There was no correlation between the affected BSA and serum concentrations of @entity16973 . CONCLUSION: Serum levels of @entity16973 can be measured by LC/ @entity15 / @entity15 . When prescribing 0.05% @entity16973 , one must bear in mind that, even after an application of 20-30 g, @entity16973 is systemically available and potent enough to induce adrenal gland suppression.
